Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT04408755 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

184

Enrollment

INDUSTRY

Sponsor class

Stopped The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.

Conditions

Agitation in Patients With Dementia of the Alzheimer's Type

Interventions

DRUG: AVP-786
DRUG: Placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.